Beijing, China - Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 15th China Interventional Therapeutics ("CIT 2017") held in China National Convention Center in Beijing from March 30 to April 2. In the CIT 2017 that continued to focus on "Cooperation, Innovation, Transition," MicroPort® released the one-year clinical and angiographic results of FUTURE I Trial for its in-house developed second-generation fully bioresorbable scaffold Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb®").
The Rhythm of MicroPort®: One-year clinical and angiographic results of Firesorb® FUTURE I released
On March 31, MicroPort® hosted a satellite meeting themed "The Rhythm of MicroPort®: From Firehawk® to Firesorb®," co-chaired by Academician Runlin Gao of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Yaling Han of the General Hospital of Shenyang Military, Dr. William Wijns of the Cardiovascular Center in Aalst of Belgium, who is also the President of EuroPCR, and Professor Alfredo E. Rodriguez from Argentina. Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences released the one-year clinical and angiographic follow-up results (clinical, angiographic, IVUS, and OCT findings) of Firesorb® FUTURE I Trial. FUTURE-I Trial is the perspective, single arm, First-in-Man ("FIM") clinical trial of evaluating the safety and efficacy of Firesorb® in the treatment of coronary heart diseases. It enrolled 45 patients. The primary endpoint is 30-day target lesion failure ("TLF"), including cardiac death, myocardial infarction of target vessel and ischemia-driven TLR (Target lesion Revascularization). The one-year clinical results showed that the occurrence of TLF is zero, the occurrence of patient-oriented composite endpoint ("PoCE") is 2.2%, and there is no death and ARC (Academic Research Consortium) defined stent thrombosis. The one-year in-device late lumen loss is 0.13mm and no restenosis occurred. MicroPort® Chief Technology Officer Dr. Qiyi Luo said: "The one-year clinical, angiographic, IVUS, and OCT results once again demonstrated Firesorb®'s feasibility, safety and efficacy in the treatment of single de novo lesions. The pivotal randomized controlled trial of Firesorb® — FUTURE II Trial was initiated in March, which is expected to provide further evidence for its safety and efficacy."
During the satellite meeting, Professor William Wijns, Dr. Andreas Baumbach of Bristol Heart Institute and Professor Junyao Zhang of Nanjing First Hospital were invited to deliver speeches. Professor William Wijns and Dr. Andreas Baumbach respectively delivered speeches of "Updates of Target AC Trial" and "Case Report from Target AC Trial." Target AC (TARGET All Comer) Trial is a perspective, randomized, multicenter, European study of Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®") designed to further assess the safety and efficacy of Firehawk® for the treatment of atherosclerotic coronary lesions in an all-comers, regardless of disease complexity and co-morbidities, real world population. Professor Junyao Zhang shared a case of "How to treat my grandfather – Accomplished early vascular healing at three months using the Firehawk® as assessed by OCT." He said, the excellent performance of Firehawk® assured him to use it in his grandfather, and the outstanding post-operative outcome further enhanced his confidence in Firehawk®.
Always be MicroPort®'s Heart: MicroPort® displays its innovative solutions
On April 1, MicroPort® hosted the Luncheon Satellite Symposium: Always be MicroPort®'s Heart, co-chaired by Professor Yuejin Yang of Fuwai Hospital of Chinese Academy of Medical Sciences, Dr. Nicolò Piazza of McGill University Health Centre, Profess Zulv Wang of General Hospital of Shenyang Military, and Professor Ning Ma of Beijing Tian Tan Hospital of Capital Medical University. Professor Minglong Chen of Jiangsu Province Hospital made a presentation on "preliminary application of domestic 3D navigation system in all kinds of complex arrhythmia." Professor Baixue Jia of Beijing Tian Tan Hospital of Capital Medical University delivered a speech on "angioplasty and/or stenting for intracranial atherosclerotic stenosis (ICAS) in Asians after SAMMPRIS." Professor Qingsheng Lu of Changhai Hospital of the Second Military Medical University introduced "aortic dissection involving the left subclavian artery." Professor Daxin Zhou of Zhongshan Hospital of Fudan University shared the "clinical application of VitaFlow® Transcatheter Aortic Valve and Delivery System." Professor Xiaohan Fan of Fuwai Hospital of Chinese Academy of Medical Sciences delivered a speech on "SAM of PM (sleep apnea monitoring function of the pacemaker) and case sharing." Their presentations fully demonstrated the innovative achievements of MicroPort® in cardiac electrophysiology, neurovascular intervention, endovascular treatment, aortic valve, and cardiac rhythm management, which was well received by attendees who also had active interactions with the speakers.
On the same day, the Endovascular Treatment of Aortic Disease Forum, co-organized by MicroPort®'s subsidiary MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular"), was held during the CIT 2017. The forum focused on "Sharing Strategies of Endovascular Treatment of Aortic Disease," and Professor Chang Shu of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Yuan Liu of Guangdong General Hospital, Professor Minxin Wei of Shenzhen Sun Yat-sen Cardiovascular Hospital, Professor Wei Li of Peking University People's Hospital, Jianing Yue of Zhongshan Hospital of Fudan University, and Xiaohui Ma of Chinese PLA General Hospital were invited for academic exchange. Professor Chang Shu delivered a speech on "treatment of aortic arch diseases," in which he explained the applications of traditional open surgery, hybrid operation and fully endovascular repair in treating aortic arch through clinical case studies. He said:" MicroPort® Endovascular's Castor™ Branched Aortic Stent Graft ("Castor™") is a promising device in the treatment of aortic arch." Professor Wei Li shared the endovascular treatment progress of thoracic/abdominal aortic aneurysms, and introduced different types of thoracic/abdominal aortic aneurysms as well as the practical solutions to aortic aneurysms in different places. He said:" Castor™ is the world's first device designed for aortic arch branch vessel reconstruction and finished FIM study. Compared with 'Chimney,' 'Fenestration' and bypass technologies, branch stent graft is more comfortable to the arch anatomy, with lowered occurrence rate of endoleak and neurological complication."
Cutting-edge Technology: Firehawk® used in Robotics PCI
During the congress, Firehawk® and Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®") were used in several live cases to show the excellent performances of MicroPort® stents. During a live case in Nanjing First Hospital on March 30, Italian expert Dr. Imad Sheiban used modified culotte technique to successfully implant three Firehawk® stents in the LM-LAD and LCX lesions of the patient. In another live case in Beijing Anzhen Hospital of Capital Medical University on April 1, Argentinian expert Alfredo E. Rodriguez used jailed wire technique to implant three Firebird2® stents in the LM-LAD and LCX lesions of the patient. Meanwhile, on March 31, the congress broadcasted a Robotics PCI case conducted in Fuwai Hospital of Chinese Academy of Medical Sciences, which is the first live broadcasting of Robotics PCI case in Asia. One Firehawk® stent was used in the case, and its excellent performance was highly recognized by experts. Professor Kefei Dou of Fuwai Hospital of Chinese Academy of Medical Sciences said: "In traditional coronary interventional treatment, physicians will inevitably be exposed to X-rays for a long time. At the same time, the operation time might be extended or extra stents might be used due to lack of precise observation of coronary artery imaging and control of device positioning. But Robotics PCI could answer to these limitations. Such technology would probably lead the future development of coronary interventional treatment."
During the CIT 2017, the VR experience center in MicroPort® booth attracted a lot of attention from the attendees. As one of the most cutting-edge technologies, VR gives the user the realistic images, sounds and other sensations that replicate a real environment or create an imaginary setting. In the VR experience center of MicroPort®, the visitor can experience the whole PCI procedure taking place in the coronary artery lesion from the perspective of the guide wire or stent. Besides, it provided visitors a more vivid understanding in coronary artery intervention devices as well as the features of Firehawk®.
In this congress, MicroPort® displayed several innovations in the cardiovascular intervention industry. As a leading high-end medical device company in China and the world, MicroPort® is dedicated to providing patients with safe, effective and affordable cardiac interventional solutions through constant innovation and integrating global experts' techniques and experience.
MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.
For more information, please refer to: www.microport.com
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.
This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.
All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989